← Eichor
Study identifier: NCT04842916 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

InteGRAtive Analysis of TuMor, Microenvironment, ImmunitY and Patient Expectation for Personalized Response Prediction in Gastric Cancer

Condition: Gastric Cancer  ·  Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

PhaseN/A
Planned participants250
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

Multicentric, exploratory, non-pharmacologic, retrospective/prospective, translational study aiming to identify the molecular, cellular and psychological-sociological variables predictive of response to chemotherapy in gastric cancer patients.

This description comes directly from the study's public registry record.

Talk to the study team

Chiara Molinari  ·  chiara.molinari@irst.emr.it

Chiara Zingaretti  ·  cc.ubsc@irst.emr.it

Always discuss trial participation with your own doctor first.

Locations (5)

Centre Hospitalier Regional et Universitaire (CHRU)Brest, FranceNot Yet Recruiting
INSERM, Faculty of Medicine (UMR1078)Brest, FranceActive Not Recruiting
1st Department of Propaedeutic Surgery, National & Kapodistrian University of Athens (NKUA)Athens, GreeceNot Yet Recruiting
IRST IRCCS UO OncologiaMeldola, ItalyRecruiting
AUSL Romagna, UO OncologiaRavenna, ItalyActive Not Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04842916